Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2019
Mar. 31, 2019
Current Assets    
Cash $ 73,412 $ 47,044
Accounts receivable, net 65,824 163,405
Inventory 105,665 78,737
Prepaids and other current assets 17,004 65,273
Total Current Assets 261,905 354,459
Property and equipment, net 372,551 452,048
Equity investments 898,292 898,292
Goodwill (provisional) 1,941,149 1,941,149
Other asset 10,133 5,500
TOTAL ASSETS 3,484,030 3,651,448
Current Liabilities    
Accounts payable 325,175 278,546
Note Payable 25,000 25,000
Convertible note payable - related party, net of debt discount of $3,565 at September 30, 2019 188,435
Convertible notes payable - unrelated parties, net of debt discount of $222,001 at September 30, 2019 277,938
Derivative liability 194,827
Accrued expenses 311,250 70,720
Total Current Liabilities 1,322,625 374,266
Commitments and Contingencies
Stockholders' Equity    
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at September 30, 2019 (unaudited) and 2018 and March 31, 2019, respectively
Common stock; $0.00001 par value; 200,000,000 shares authorized: 13,547,110 issued and outstanding at September 30, 2019 (unaudited) and 13,397,110 at March 31, 2019 137 135
Stock subscription receivable
Additional paid in capital $ 7,089,621 $ 6,892,242
Common stock to be issued, 512,651 shares at September 30, 2019 (unaudited) and 408,805 shares at March 31, 2019 823,807 773,807
Accumulated deficit $ (6,732,903) $ (5,531,260)
Total Applied BioSciences Corp. Stockholders' Equity 1,180,662 2,134,924
Non-controlling deficit 980,743 1,142,258
Total Stockholders' Equity 2,161,405 3,277,182
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 3,484,030 $ 3,651,448